title: [Acidosis without marked hyperglycemia : Euglycemic diabetic ketoacidosis associated with SGLT2-Inhibitors].
abstract: Sodium-glucose cotransporter 2 (SGLT2) inhibitors are new antidiabetic drugs that regulate blood glucose levels by increasing urinary glucose excretion. In May 2015, the U.S. Food and Drug Administration (FDA) issued a warning that SGLT2 inhibitors may lead to ketoacidosis. In this report, we describe a case of life-threatening euglycemic ketoacidosis associated with SGLT2 inhibition and evaluate possible mechanisms and triggers.
authors.affiliation: Anästhesie und Intensivmedizin, Stadtspital Triemli, Birmensdorferstraße 497, 8063, Zürich, Schweiz. ruth.valek@triemli.zuerich.ch.
authors.forename: R
authors.initials: R
authors.lastname: Valek
authors.affiliation: Anästhesie und Intensivmedizin, Stadtspital Triemli, Birmensdorferstraße 497, 8063, Zürich, Schweiz.
authors.forename: J
authors.initials: J
authors.lastname: Von der Mark
mesh_terms: D001559:Benzhydryl Compounds / Q000009:adverse effects / Q000627:therapeutic use; D001786:Blood Glucose / Q000378:metabolism*; D003131:Combined Modality Therapy; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy*; D016883:Diabetic Ketoacidosis / Q000097:blood* / Q000139:chemically induced* / Q000628:therapy; D004359:Drug Therapy, Combination; D005960:Glucosides / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D000069036:Insulin Glargine / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008687:Metformin / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D012307:Risk Factors; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors
chemical_list: D001559:Benzhydryl Compounds; D001786:Blood Glucose; D005960:Glucosides; D007004:Hypoglycemic Agents; C089180:SLC5A2 protein, human; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors; C529054:dapagliflozin; D000069036:Insulin Glargine; D008687:Metformin
keywords: Adverse effects; Diabetes mellitus typ 2; Diabetic ketoacidosis; Oral anti-diabetics; SGLT2 inhibitors